Impact of NK cell repertoires on immunotherapy in acute myelod leukemia
Abstract
Natural killer (NK) cells are lymphocytes endowed with cytotoxicity against aberrant cells, including transformed and virus-infected cells. NK cell function is dictated by a fine-tuned interplay between activating and inhibitory receptors expressed on the NK cell surface. While the different activating receptors interact with unique ligands present on healthy or transformed cells, inhibitory NKG2A and killer immunoglobulin-like receptors (KIRs) invariably recognize HLA class I molecules. The purpose of this thesis was to elucidate how interactions between inhibitory NK cell receptors and HLA class I impact on anti-leukemic functions of NK cells and on NK cell-mediated termination of inflammation. In a phase IV trial, 81 AML patients received histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for the prevention of recurrence of leukemia after the completion of chemotherapy. The trial comprised immunophenotyping of serial blood samples along with KIR/HLA genotyping and assessment of cytomegalovirus (CMV) serostatus. Results from papers I and II imply a beneficial role of NK cell subsets that are less inhibited by HLA while prior CMV infection, which promotes the expression of additional KIRs, impacted negatively on relapse risk and survival. Additionally, a single nucleotide polymorphism in HLA-B that dictates NK cell inhibition to be preferentially mediated by NKG2A impacted positively on outcome in this trial (paper III). The relevance of the interplay between activating and HLA-mediated inhibitory signaling was further illustrated in a non-malignant setting in paper IV, where modulation of NK cell receptor ligands expressed by inflammatory neutrophils was associated with enhanced susceptibility to NK cell cytotoxicity. In conclusion, these studies support i) that low-grade KIR-mediated inhibition of NK cells is relevant for the benefit of relapse-preventive immunotherapy in AML and ii) that NK cells participate in the resolution of inflammation.
Parts of work
I. Bernson E, Hallner A, Sander F E, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén F B. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia, 2017; Epub ahead of print ::PMID::28529313 II. Bernson E, Hallner A, Sander F E, Nicklasson M, Nilsson M, Christenson K, Aydin E, Liljeqvist J-Å, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén F B. Cytomegalovirus regulates autoreactive NK cells and prognosticates the outcome of IL-2-based immunotherapy in acute myeloid leukemia. Submitted III. Hallner A, Bernson E, Hussein B A, Sander F E, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén F B. Impact of HLA-B -21 dimorphism on clinical outcome of IL-2-based immunotherapy in acute myeloid leukemia. In manuscript IV. Bernson E*, Christenson K*, Pasanen M, Hellstrand K, Bylund J, Thorén F T. Dynamic modulation of NK cell receptor ligands in inflammatory neutrophils. In manuscript. *Authors contributed equally
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Biomedicine. Department of Infectious Diseases
Disputation
Torsdagen den 30 november 2017, kl. 9.00, Hörsal Arvid Carlsson, Medicinaregatan 3, Göteborg
Date of defence
2017-11-30
elin.bernson@gu.se
Date
2017-11-08Author
Bernson, Elin
Keywords
Natural killer cells
Acute myeloid leukemia
Immunotherapy
Killer-cell imunoglobulin-like receptor
Human leukocyte antigen class I molecules
Publication type
Doctoral thesis
ISBN
978-91-629-0339-8 (pdf)
978-91-629-0338-1 (print)
Language
eng